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the United States, Europe and Canada
Abstract

The requirement that an invention have utility is one of the most fundamental of the patent laws. In the United
States, for example, the concept of utility is rooted in the Constitution: Article 1, Section 8, gives Congress the
power to grant exclusive rights to inventors in order “[t]o promote the progress of Science and useful Arts.”
Other jurisdictions recognize utility in the form of inventions that have “industrial applicability” or are
“capable of exploitation in industry,” with all of these terms and phrases generally viewed as being
synonymous.
Historically, nearly every jurisdiction has excluded some type of invention from patentability as lacking utility.
A common and enduring utility-based exclusion is the perpetual motion machine, with the justification being
scientific: because perpetual motion is not physically possible, an invention which claims such a feature
cannot in fact work and therefore fundamentally lacks utility. Jurisdictions also make exclusions on policy
grounds. In Europe, for example, methods of treating human and animal bodies are not patentable, but the
justification for doing so, which previously was based on lack of industrial applicability, is now expressly linked
to public health policy. In an ever-more global economy, inventions are at the heart of commercial transactions
that know no geographic boundaries and are increasingly valued for their job and wealth creation. Obtaining
patent protection in multiple jurisdictions therefore is increasingly common. At least to reduce costs and
increase efficiency, patent owners, policymakers and practitioners alike have sought increased inter
jurisdictional cooperation and patent law harmonization in the patent examination and granting process.
Recent publications, however, have identified a developing trend in Canada in which Canadian courts and the
Canadian Intellectual Property Office are interpreting and applying the historically well-settled and generally
harmonized utility requirement in a new and different way, in particular with respect to patents for
pharmaceutical products. As a result, applicants for Canadian patents must meet conditions and overcome
hurdles not required by other major patent offices.
This article will compare Canada’s implementation and treatment of the utility requirement with the
implementation and treatment practiced in the United States and Europe—two jurisdictions that represent
prevailing approaches to utility and also constitute a major share of the world’s patenting activity. The article
will first examine the statutory and judicial situation in each of the jurisdictions, including a review of the
major international treaties and agreements to which each is subject. It will then present a case study that
looks at the judicial challenges brought against various members of a single patent family in the United States,
Europe, and Canada, and compare the results of those challenges. This analysis, we believe, reveals that the
recent shift in Canada’s approach to the utility requirement conflicts with international norms and thus
presents implications for patentees, patent law harmonization, and international treaty obligations.
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INTRODUCTION

The requirement that an invention have utility is one of the most fundamental
of the patent laws. In the United States, for example, the concept of utility is
rooted in the Constitution: Article 1, Section 8, gives Congress the power to grant
exclusive rights to inventors in order “[t]o promote the progress of Science and
useful Arts.”1 Other jurisdictions recognize utility in the form of inventions that
have “industrial applicability”2 or are “capable of exploitation in industry,”3 with
all of these terms and phrases generally viewed as being synonymous.4
Historically, nearly every jurisdiction has excluded some type of invention
from patentability as lacking utility.5 A common and enduring utility-based
exclusion is the perpetual motion machine, with the justification being scientific:
because perpetual motion is not physically possible, an invention which claims
such a feature cannot in fact work and therefore fundamentally lacks utility.6
Jurisdictions also make exclusions on policy grounds. In Europe, for example,
methods of treating human and animal bodies are not patentable, but the
justification for doing so, which previously was based on lack of industrial
applicability,7 is now expressly linked to public health policy.8
1

U.S. CONST. art. I, § 8, cl. 8 (emphasis added).
See WORLD INTELLECTUAL PROP. ORG., PATENT COOPERATION TREATY INTERNATIONAL
SEARCH AND PRELIMINARY EXAMINATION GUIDELINES, § A14.01[1] (Oct. 3, 2011) [hereinafter
PCT GUIDELINES], available at http://www.wipo.int/pct/en/texts/pdf/ispe.pdf.
3
See EUROPEAN PATENT OFFICE, GUIDELINES FOR EXAMINATION IN THE EUROPEAN PATENT
OFFICE, pt. C, ch. II, § 4.12 (Apr. 2010) [hereinafter EPO EXAMINATION GUIDELINES] (referring to
French and German texts of the European Patent Convention), available at
http://documents.epo.org/projects/babylon/eponet.nsf/0/7ffc755ad943703dc12576f00054cacc/$FI
LE/guidelines_2010_complete_en.pdf.
4
See PCT GUIDELINES, supra note 2.
5
See Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364, 1367–68 (Fed. Cir. 1999)
(“[Y]ears ago courts invalidated patents on gambling devices on the ground that they were
immoral, but that is no longer the law . . . . ‘Congress never intended that the patent laws should
displace the police powers of the States, meaning by that term those powers by which the health,
good order, peace and general welfare of the community are promoted.’ . . . [W]e find no basis in
section 101 to hold that inventions can be ruled unpatentable for lack of utility simply because
they have the capacity to fool some members of the public.”) (citations omitted); see also U.S.
PATENT & TRADEMARK OFFICE, U.S. DEP’T COMMERCE, MPEP § 706.03(II) (8th ed. Rev. 8, July
2010) [hereinafter MPEP].
6
See MPEP, supra note 5, § 706.03(II) (“A rejection on the ground of lack of utility includes
the more specific grounds of inoperativeness, involving perpetual motion.”); EPO EXAMINATION
GUIDELINES, supra note 3, pt. C, ch. II, § 4.11 (“[S]uccessful performance of the invention is
inherently impossible because it would be contrary to well-established physical laws – this applies
e.g. to a perpetual motion machine.”).
7
European Patent Convention art. 52(4), Oct. 5, 1973, 1065 U.N.T.S. 199 (1973) [hereinafter
EPC-1973], available at http://www.epo.org/law-practice/legal-texts/html/epc/1973/e/ar52.html
2
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In an ever-more global economy, inventions are at the heart of commercial
transactions that know no geographic boundaries and are increasingly valued for
their job and wealth creation. Obtaining patent protection in multiple jurisdictions
therefore is increasingly common.9 At least to reduce costs and increase
efficiency,10 patent owners, policymakers and practitioners alike have sought
increased interjurisdictional cooperation and patent law harmonization in the
patent examination and granting process.11 Recent publications, however, have

(“Methods for the treatment of the human or animal body by surgery or therapy and diagnostic
methods practised on the human or animal body shall not be regarded as inventions which are
susceptible of industrial application within the meaning of [Article 52(1)].” (emphasis added)).
8
European Patent Convention art. 53(c), Oct. 5, 1973, 1065 U.N.T.S. 199 (as amended Nov.
29,
2000)
[hereinafter
EPC-2000],
available
at
http://documents.epo.org/projects/babylon/eponet.nsf/0/7bacb229e032863dc12577ec004ada98/$F
ILE/EPC_14th_edition.pdf; Shamnad Basheer et al., Patent Exclusions that Promote Public
Health Objectives, in AN EXPERT’S STUDY ON EXCLUSIONS FROM PATENTABLE SUBJECT MATTER
AND EXCEPTIONS AND LIMITATIONS TO THE RIGHTS Annex IV (2010) available at
http://www.wipo.int/edocs/mdocs/scp/en/scp_15/scp_15_3-annex4.pdf (last visited Feb. 16, 2012)
(“The European Patent Convention (EPC) categorically excludes ‘methods of medical and
veterinary treatment’ from patentability. Such inventions are excluded to ensure that people who
carry out medical or veterinary treatments are not inhibited by patents.”).
9
World Intellectual Prop. Org. [WIPO], World Intellectual Property Indicators (2011),
available
at
http://www.wipo.int/export/sites/www/freepublications/en/intproperty/941/wipo_pub_941_2011.p
df. “The trend in total patent families was stable until 1994 and has followed an upward trend
since then . . . . Meanwhile, the number of foreign-oriented patent families more than doubled –
from 107,318 in 1985 to 257,321 in 2008 – reflecting the increasing tendency for applicants to file
abroad.” Id. at 56–57. The United States leads all others in foreign-oriented patent family filings
(i.e., families for which the first-filed application in a family is foreign) with 22.3% of all foreignoriented families including a filing at the U.S. Patent & Trademark Office (USPTO), followed by
the European Patent Office (EPO) (19.3%), China (52.2%) and Canada (46.9%). Id. at 59. With
respect to residents, 49.4% of all applications filed in the USPTO in 2010 were filed by U.S.
residents, which is similar to the EPO’s 49.3%; in Canada, only 12.8% of applications were filed
by Canadian residents in 2010. Id. at 43.
10
JAKKRIT KUANPOTH, PATENT RIGHTS IN PHARMACEUTICALS IN DEVELOPING COUNTRIES:
MAJOR CHALLENGES FOR THE FUTURE 12 (Edward Elgar Publ’g. Ltd. 2010) (“[A]ttempts have
been made to establish regional co-operation regarding patent administration in order to increase
efficiency and reduce costs of granting and maintaining patents. In recent years, there has been a
drive from certain countries towards the increased harmonization of patent law standards as well
as patent granting procedures.”).
11
See, e.g., David Kappos,Under Sec’y for Commerce for Intellectual Prop. & Dir. of the U.S.
Patent & Trademark Office, Remarks as prepared for delivery at the WIPO Symposium –
Promoting Innovation & Creativity: The America Invents Act and a Global Call for
Harmonization,
(Sept.
22,
2011)
(transcript
available
at
http://www.uspto.gov/news/speeches/2011/kappos_wipo.jsp) (“I’ll make the case for the urgency
of harmonization, a mandate to better manage the collective challenges our global IP system faces
in a 21st century economy. The public must have confidence that the patent system is striking the
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identified a developing trend in Canada in which Canadian courts and the
Canadian Intellectual Property Office are interpreting and applying the
historically well-settled and generally harmonized utility requirement in a new
and different way, in particular with respect to patents for pharmaceutical
products.12 As a result, applicants for Canadian patents must meet conditions and
overcome hurdles not required by other major patent offices.
This article will compare Canada’s implementation and treatment of the utility
requirement with the implementation and treatment practiced in the United States
and Europe—two jurisdictions that represent prevailing approaches to utility and
also constitute a major share of the world’s patenting activity. The article will
first examine the statutory and judicial situation in each of the jurisdictions,
including a review of the major international treaties and agreements to which
each is subject. It will then present a case study that looks at the judicial
challenges brought against various members of a single patent family in the
United States, Europe, and Canada, and compare the results of those challenges.
This analysis, we believe, reveals that the recent shift in Canada’s approach to the
utility requirement conflicts with international norms and thus presents
implications for patentees, patent law harmonization, and international treaty
obligations.

right balance between incentives to innovate and access to those new innovations. Through global
synergy and collaboration, we have a unique opportunity, right away, to meet these challenges –
and I believe it is imperative we do that, and act by moving towards a more standardized global
patent system.”); Dongwook Chun, Patent Law Harmonization in the Age of Globalization: The
Necessity and Strategy for Pragmatic Outcome, 93 J. PAT. & TRADEMARK OFF. SOC’Y 127, 138
(2011) (“The majority of the international patent community is and has been supportive of the idea
of uniformity, recognizing the value of creating a uniform patent law on a global scale.”); Dennis
Crouch, Some Hope for the Patent Reforms, PATENTLY-O (Sept. 7, 2011),
http://www.patentlyo.com/patent/2011/09/by-dennis-crouch-at-this-point-it-appears-very-likelythat-the-leahy-smith-america-invents-act-hr-1249-will-become-law-a.html
(“Many
patent
applications are independently and redundantly examined in patent offices around the world. That
scenario appears ripe for some level of cooperation and coordination that could seemingly reduce
delay and costs while improving quality.”).
12
See, e.g., Charles E. Lipsey & L. Scott Burwell, Useful in the United States, But Not in
Canada: Divergent Applications of the Statutory Utility Requirements, BLOOMBERG LAW
REPORTS,
Oct.
3,
2011,
available
at
http://www.finnegan.com/resources/articles/articlesdetail.aspx?news=59ab301b-1d14-441d-85db67b67f9243ed; Arvie Anderson & Lawrence Welch, The Canadian Patent Promise: A Concern
for Pharmaceutical Innovators?, IPO COMMITTEE NEWSL. (Intellectual Prop, Owner’s Assoc.,
Washington,
D.C.),
Dec.
2011,
available
at
http://www.morganlewis.com/pubs/IP_IPOIsolatedDNASequences_dec2011.pdf. This selective
application is significant because, in 2009 alone, 62,122 pharmaceutical patent applications were
filed worldwide; from 2005 to 2009, 5,584 were filed in Canada. World Intellectual Property
Indicators, supra note 9, at 76–77.
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AN OVERVIEW OF UTILITY IN THE UNITED STATES, EUROPE & CANADA

Utility requirements for patent applications are one of the most basic and
fundamental. In general, a common theme exists across jurisdictions about what
might be “useful.”13 It is agreed that some level of utility (or “industrial
applicability,” as it is known in Europe14) must be shown, but the question is how
much or to what degree. Following the 2002 decision by the Supreme Court of
Canada in Apotex Inc. v. Wellcome Foundation Ltd.,15 as expanded by the
Canadian Court of Appeal in Eli Lilly Canada Inc. v. Apotex Inc.,16 Canada began
requiring that patent applicants do more to prove utility prior to filing than is
required by other jurisdictions and international agreements. To begin to put this
assertion into context, this section discusses the respective statutory laws, patent
office administrative rules, and jurisprudence of the United States, Europe, and
Canada.
A. United States
In the United States, § 101 of the Patent Act defines what is patentable:
“Whoever invents or discovers any new and useful process, machine,
manufacture, or composition of matter, or any new and useful improvement
thereof may obtain a patent therefor, subject to the conditions and requirements of
this title.”17 To satisfy § 101, an applicant must claim an invention that falls
within one of the categories of statutory subject matter and show that that claimed
invention is useful.18
The Manual of Patent Examination Procedure (MPEP) administered by the
United States Patent & Trademark Office (USPTO) provides examination
13

See, e.g., Brenner v. Manson, 383 U.S. 519, 536 (1966) (“But a patent is not a hunting
license. It is not a reward for the search, but compensation for its successful conclusion. ‘[A]
patent system must be related to the world of commerce . . . .’” (quoting Application of Ruschig,
343 F.2d 965, 970 (C.C.P.A. 1965)); PCT GUIDELINES, supra note 2.
14
See infra Part II.B.
15
[2002] 4 S.C.R. 153 (Can.).
16
[2009] F.C.A. 97, para. 18 (Can.) (The Court expressly required that a patent specification
must include “a disclosure such that a person skilled in the art, given that disclosure, could have as
the inventors did, soundly predicted that the invention would work once reduced to practice.”
(emphasis added)).
17
35 U.S.C. § 101 (2006) (emphasis added); see also MPEP, supra note 5, § 2107.01. Section
101 was not amended by the recent America Invents Act. See Leahy-Smith America Invents Act
of 2011, Pub. L. No. 112-29, 125 Stat. 284.
18
MPEP, supra note 5, § 2107.01 (“As interpreted by the Federal courts, 35 U.S.C. 101 has
two purposes. First, 35 U.S.C. 101 defines which categories of inventions are eligible for patent
protection. An invention that is not a machine, an article of manufacture, a composition or a
process cannot be patented. Second, 35 U.S.C. § 101 serves to ensure that patents are granted on
only those inventions that are ‘useful.’” (citations omitted)).
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guidelines for the utility requirement of § 101.19 To demonstrate that an invention
is useful, an applicant must show that the invention has “specific and substantial
utility” or discloses sufficient information about the invention such that its utility
is immediately apparent to those familiar with the technological field, so-called
“well-established utility.”20
Specific utility must be specific to the subject matter of the claimed invention
and not merely generally applicable to the “broad class of the invention.”21 For
example, a statement that an invention is useful to diagnose disease without
disclosing a particular disease or condition would lack specific utility, whereas
one that discloses a biological activity and “reasonably correlates that activity to a
disease condition” would establish sufficient specific utility.22
Substantial utility can be equated to showing a “real world” use. 23 To
establish substantial utility, an applicant must show that an invention is useful as
disclosed in its current form, rather than at some time in the future pending
additional research.24 “Utilities that require or constitute carrying out further
research to identify or reasonably confirm a ‘real world’ context of use are not
substantial utilities.”25 The MPEP is careful to qualify, however, that “in its
19

Id. § 2107.01. The MPEP further provides that inventions in various different technological
fields are each subject to the same legal requirements with respect to utility, there being “no basis
in the statutes or decisions for requiring any more conclusive evidence of operativeness in one
type of case than another.” Id. § 2107.01(III) (citing In re Chilkowsky, 229 F.2d 457, 461–62
(C.C.P.A. 1956)). “Courts have repeatedly found that the mere identification of a pharmacological
activity of a compound that is relevant to an asserted pharmacological use provides an ‘immediate
benefit to the public’ and thus satisfies the utility requirement.” MPEP, supra note 6, §
2107.01(III).
20
MPEP, supra note 5, § 2107.01 (citing Brenner v. Manson, 383 U.S. 519, 148 U.S.P.Q. 689
(1966); In re Fisher, 421 F.3d 1365, 76 U.S.P.Q.2d 1225 (Fed. Cir. 2005); In re Ziegler, 992 F.2d
1197, 26 U.S.P.Q.2d 1600 (Fed. Cir. 1993)). See also MPEP, supra note 5, § 2107.02(II) (“An
invention has a well-established utility if (i) a person of ordinary skill in the art would
immediately appreciate why the invention is useful based on the characteristics of the invention
(e.g., properties or applications of a product or process), and (ii) the utility is specific, substantial,
and credible.”).
21
MPEP, supra note 5, § 2107.01(I)(A). Many of the examples of specific vs. general utility
provided in the MPEP are related to pharmacological and biotech inventions. “[I]ndicating that a
compound may be useful in treating unspecified disorders, or that the compound has ‘useful
biological’ properties, would not be sufficient to define a specific utility for the compound.” Id.
22
Id. “Assertions that fall in the former category are insufficient to define a specific utility for
the invention, especially if the assertion takes the form of a general statement that makes it clear
that a ‘useful’ invention may arise from what has been disclosed by the applicant.” Id.
23
MPEP, supra note 5, § 2107.01(I)(B).
24
Id. (citing In re Fisher, 421 F.3d at 1371).
25
MPEP, supra note 5, § 2107.01(I)(B) (“For example, both a therapeutic method of treating a
known or newly discovered disease and an assay method for identifying compounds that
themselves have a ‘substantial utility’ define a ‘real world’ context of use. An assay that measures
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current form” is not intended to mean that a claimed invention must be “currently
available,” but rather that any reasonable use that is identified by the applicant
and can be seen to provide a public benefit is sufficient to establish substantial
utility.26
A deficiency under § 101 generally leads to a deficiency under § 112 , the first
paragraph of which provides that the specification of a patent application:
[S]hall contain a written description of the invention, and of the
manner and process of making and using it, in such full, clear,
concise, and exact terms as to enable any person skilled in the art
to which it pertains, or with which it is most nearly connected, to
make and use the same, and shall set forth the best mode
contemplated by the inventor of carrying out his invention.27
Section 112 therefore has been interpreted to set forth three separate
requirements: written description, enablement, and best mode.28
The
interrelationship between §§ 101 and 112 stems from the reasoning that if an
invention lacks utility, an application for that invention cannot enable one to use
it.29 Therefore, rejections for lack of utility typically implicate both §§ 101 and
112.30

the presence of a material which has a stated correlation to a predisposition to the onset of a
particular disease condition would also define a ‘real world’ context of use in identifying potential
candidates for preventive measures or further monitoring. On the other hand, the following are
examples of situations that require or constitute carrying out further research to identify or
reasonably confirm a ‘real world’ context of use and, therefore, do not define ‘substantial utilities’:
(A) Basic research such as studying the properties of the claimed product itself or the mechanisms
in which the material is involved; (B) A method of treating an unspecified disease or condition;
(C) A method of assaying for or identifying a material that itself has no specific and/or substantial
utility; (D) A method of making a material that itself has no specific, substantial, and credible
utility; and (E) A claim to an intermediate product for use in making a final product that has no
specific, substantial and credible utility.”)
26
Id.
27
35 U.S.C. § 112 (2006).
28
See, e.g., University of Rochester v. G.D. Searle & Co., 358 F.3d 916, 921 (Fed. Cir. 2004).
Best mode will be affected by the recently enacted America Invents Act in that it will no longer be
available as an invalidity defense in litigation, but the requirement of § 112 will remain as a
requirement of patentability. Leahy-Smith America Invents Act of 2011, supra note 17, § 15.
29
See In re Ziegler, 992 F.2d 1197, 1200–01 (Fed. Cir. 1993); see also MPEP, supra note 5, §
2107.01(IV).
30
MPEP, supra note 5, § 2107.01(IV) (“The fact that an applicant has disclosed a specific
utility for an invention and provided a credible basis supporting that specific utility does not
provide a basis for concluding that the claims comply with all the requirements of 35 U.S.C. 112,
first paragraph. For example, if an applicant has claimed a process of treating a certain disease
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An asserted utility, that is, a statement in the patent application that the
claimed invention is useful for some purpose, creates a presumption of utility.31
If the asserted utility is “credible,” rejection for lack of utility is inappropriate. 32
Examiners will treat an assertion as credible unless: (1) the logic underlying the
assertion is seriously flawed; or (2) the facts upon which the assertion is based are
inconsistent with the logic underlying the assertion.33 The standard for
overcoming the presumption of utility is that it is more likely than not that one of
ordinary skill in the art would doubt or question the truth of the statement of
utility.34 In some situations, an examiner may request additional information
from an applicant to support an asserted utility, for example, if an asserted utility
is one that would seem unlikely to one of ordinary skill in the art. 35 Such
requests, however, should be imposed “rarely, and only if necessary to support the
scientific credibility of the asserted utility.”36
Fundamentally, the MPEP states that “[t]here is no predetermined amount or
character of evidence that must be provided by an applicant to support an asserted
utility, therapeutic or otherwise. Rather, the character and amount of evidence
needed to support an asserted utility will vary depending on what is claimed.”37
The MPEP specifically addresses “special considerations” related to therapeutic
and pharmacologic utilities, providing that in those areas, too, “all that is required

condition with a certain compound and provided a credible basis for asserting that the compound
is useful in that regard, but to actually practice the invention as claimed a person skilled in the
relevant art would have to engage in an undue amount of experimentation, the claim may be
defective under 35 U.S.C. 112, but not 35 U.S.C. 101.”)
31
See, e.g., In re Langer, 503 F.2d 1380, 1391 (C.C.P.A. 1974); see also MPEP, supra note 5,
§ 2107.02(III)(A). The asserted utility, however, must be commensurate in scope with the claimed
subject matter. Id.
32
Id.
33
MPEP, supra note 5, § 2107.02(III)(B). Note that “[s]pecial care should be taken when
assessing the credibility of an asserted therapeutic utility for a claimed invention. In such cases, a
previous lack of success in treating a disease or condition, or the absence of a proven animal
model for testing the effectiveness of drugs for treating a disorder in humans, should not, standing
alone, serve as a basis for challenging the asserted utility under 35 U.S.C. 101.” Id.
34
See In re Langer, 503 F.2d at 1391; see also MPEP, supra note 5, § 2107.02(III)(A). U.S.
courts generally are reluctant to uphold § 101 rejections “solely on the basis that the applicant’s
opinion as to the nature of the specific and substantial utility was inaccurate.” Id. § 2107.01(I);
see also Nelson v. Bowler, 626 F.2d 853, 856 (C.C.P.A. 1980) (finding that proof of any
pharmacological activity of a drug was sufficient to find “practical utility”).
35
MPEP, supra note 5, § 2107.02(V) (citing In re Pottier, 376 F.2d 328, 330 (C.C.P.A. 1967)).
36
Id.
37
MPEP, supra note 6, § 2107.02(VII).

[3:1 2012]

Usefulness Varies by Country:
The Utility Requirement of Patent Law
in the United States, Europe and Canada

9

is a reasonable correlation between the activity and the asserted use.”38
Furthermore, courts in the United States generally are not receptive to rejections
under § 101 for lack of utility, with the MPEP noting that it is “striking” that §
101 rejections were almost always overturned where a reasonable evidentiary
showing supporting an asserted therapeutic utility was made by the applicant.39
The MPEP also reminds examiners that, with respect to therapeutic and
pharmacologic inventions, the role of the USPTO is to examine patent
applications with respect to the patent laws, not determine whether, e.g., a drug is
safe for sale, use or distribution.40
In re Fisher, a 2005 decision of the United States Court of Appeals for the
Federal Circuit, illustrates the approach to the utility requirement adopted in the
United States.41 In Fisher, the patentee sought to patent certain “expressed
sequence tags,” or “ESTs,” but was rejected for failing to express a specific utility
for the ESTs, as the disclosed genes for which the ESTs corresponded had no

38

MPEP, supra note 5, § 2107.03(I) (“An applicant can establish this reasonable correlation by
relying on statistically relevant data documenting the activity of a compound or composition,
arguments or reasoning, documentary evidence (e.g., articles in scientific journals), or any
combination thereof. The applicant does not have to prove that a correlation exists between a
particular activity and an asserted therapeutic use of a compound as a matter of statistical
certainty, nor does he or she have to provide actual evidence of success in treating humans where
such a utility is asserted.” (citing Nelson v. Bowler, 626 F.2d 853, 857 (C.C.P.A. 1980)).
39
MPEP, supra note 5, § 2107.03(III). “In no case has a Federal court required an applicant to
support an asserted utility with data from human clinical trials.” Id. Regarding human clinical
trials, the USPTO:
[S]hould not impose on applicants the unnecessary burden of providing evidence
from human clinical trials. There is no decisional law that requires an applicant
to provide data from human clinical trials to establish utility for an invention
related to treatment of human disorders . . . . Before a drug can enter human
clinical trials, the sponsor, often the applicant, must provide a convincing
rationale to those especially skilled in the art (e.g., the Food and Drug
Administration) that the investigation may be successful. Such a rationale would
provide a basis for the sponsor’s expectation that the investigation may be
successful. In order to determine a protocol for phase I testing, the first phase of
clinical investigation, some credible rationale of how the drug might be effective
or could be effective would be necessary. Thus, as a general rule, if an
applicant has initiated human clinical trials for a therapeutic product or
process, Office personnel should presume that the applicant has established that
the subject matter of that trial is reasonably predictive of having the asserted
therapeutic utility.
MPEP, supra note 5, § 2107.03(IV).
40
Id. § 2107.03(V).
41
In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005).
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known function at the time.42 On appeal, Fisher asserted that the Board of Patent
Appeals and Interferences (BPAI) incorrectly applied a heightened utility
standard.43 The Federal Circuit rejected the argument holding that the proposed
utility failed to meet the ordinary utility standard.44 The court reasoned that a
claimed invention whose only stated utility was use with genes that have no
known use cannot be reasonably found to meet the utility standard. 45 Fisher
exemplifies the United States approach to the utility requirement, namely that the
requirement is met so long as the specified utility is reasonable and not an attempt
to create a utility where none exists.
B. Europe
Although Europe46 uses a different term to describe the standard, its approach
to the utility requirement is remarkably similar to that of the United States. The
European Patent Convention (EPC) establishes that inventions which are new,
involve an inventive step, and are susceptible of industrial application are
patentable.47 Being “susceptible of industrial application” is Europe’s form of
“utility,” and an invention is susceptible of industrial application if “it can be
made or used in any kind of industry.”48 Rule 42 of the Implementing
Regulations of the EPC deals with the content of the description that must be
provided in a European patent application and states that the description shall
“indicate explicitly, when it is not obvious from the description or nature of the
invention, the way in which the invention is industrially applicable.”49
42

Id. at 1368–69.
Id. at 1369–70.
44
Id. at 1374.
45
Id.
46
Here “Europe” refers to the European Patent Organisation, an intergovernmental
organization established in 1977 on the basis of the European Patent Convention. See infra notes
47–61 and accompanying text. The European Patent Organisation has two bodies, the European
Patent Office (EPO) and the Administrative Council. The Administrative Council of the European
Patent
Organisation,
EUROPEAN
PAT.
OFF.,
http://www.epo.org/aboutus/organisation/administrative-council.html (last updated Feb. 2, 2011). See infra note 61 and
accompanying text for a discussion regarding the national laws of the European countries.
47
EPC-2000, supra note 8, art. 52. Discoveries, scientific theories and mathematical methods;
aesthetic creations; schemes, rules and methods for performing mental acts, playing games or
doing business, and programs for computers; and presentations of information are all specifically
excluded from patentability. Id.
48
Id. art. 57. “Industry” generally is understood to mean “in its broadest sense.” See EPO
EXAMINATION GUIDELINES, supra note 3, pt. C, ch. IV, § 5.1; WIPO, STANDING COMMITTEE ON
THE LAW OF PATENTS, “Industrial Applicability” and “Utility” Requirements: Commonalities and
Differences,
SCP/9/5
¶¶
4,
12
(Mar.
17,
2003),
available
at
http://www.wipo.int/edocs/mdocs/scp/en/scp_9/scp_9_5.pdf.
49
EPC-2000, supra note 8, at R. 42(1)(f).
43
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Examiners follow the Guidelines for Examination in the European Patent
Office (EPO Examination Guidelines) to examine patent applications.50 The EPO
Examination Guidelines begin by defining, in accordance with the EPC, that there
are four basic requirements for patentability in Europe: (1) there must be an
invention, belonging to any field of technology; (2) the invention must be
susceptible of industrial application; (3) the invention must be new; and (4) the
invention must involve an inventive step.51
With respect to industrial application, the EPO Examination Guidelines state
that “[t]he description should indicate explicitly the way in which the invention is
capable of exploitation in industry.”52 The EPC hypothesizes that:
[I]n most cases, the way in which the invention can be exploited in
industry will be self-evident, so that no more explicit description
on this point will be required; but there may be a few instances,
e.g., in relation to methods of testing, where the manner of
industrial exploitation is not apparent and must therefore be
explicitly indicated.53
In one case, the EPO Technical Board of Appeal considered an appeal of a refusal
of claims as being not susceptible of industrial application under EPC Article
57.54 Claim 1 of the application at issue was directed to a method of improving
the bodily appearance of a non-opiate-addicted mammal by orally administering
naltrexone or a pharmaceutically effective salt thereof in order to reduce appetite,
and repeating the dosage until a “cosmetically” beneficial loss of body weight
occurred.55 The specific ground for refusing the claims was that the subject
matter was directed to a cosmetic process not susceptible of industrial
application.56
In its appeal, Appellant E.I. Du Pont De Nemours & Co. argued that “the
claims need not necessarily be restricted to industrial application” and that “[t]he

50

See EPO EXAMINATION GUIDELINES, supra note 3.
Id. pt. C, ch. IV, § 1.1. Also, with respect to gene sequences specifically, “The invention
claimed must have such a sound and concrete technical basis that the skilled person can recognise
that its contribution to the art could lead to practical exploitation in industry.” Id. § 5.4.
52
Id. pt. C, ch. II, § 4.12.
53
Id.
54
Case T-144/83, E.I. du Pont de Nemours & Co., 1986 O.J. E.P.O. 301, available at
http://archive.epo.org/epo/pubs/oj1986/p295_336.pdf.
55
Id. at 302.
56
Id. (“The treatment of a human being with such a drug was essentially biological in nature
and therefore the administration of the same could not be regarded as susceptible to industrial
application.”).
51
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word ‘industry’ should be given a broad interpretation . . . .”57 The Board of
Appeals agreed, finding the subject matter of the claims was patentable under
former EPC Article 52(4).58
According to the provision of [EPC Article 52(4)] methods for
treatment of the human or animal body by therapy shall not be
regarded as susceptible to industrial application. Such exclusions
from patentability must be construed narrowly and should not
apply to treatments which are not therapeutic in character . . . .
[Claim 1] clearly covers a method of cosmetic use and is unrelated
to the therapy of human or animal body in the ordinary sense.59
The invention was also found to comply with EPC Article 57 (Industrial
Application) because the invention “can be used by enterprises whose object is to
beautify the human or animal body,” and such enterprises in the cosmetic field are
part of industry since “‘industry’ implies that an activity is carried out
continuously, independently and for financial gain.”60
Thus, while the terminology varies (“utility” in the United States but
“susceptible of industrial application” in Europe), the approaches of the
jurisdictions are very similar with respect to the level of disclosure required and
the deference given to asserted utility. The same approach has been adopted by
the individual countries of Europe, the national laws of which tend to reflect the
EPC and therefore will not be discussed individually herein.61

57

Id. at 303.
Id. at 304; Act Revising the Convention on the Grant of European Patents, June 28, 2001,
2007 O.J. E.P.O. SPEC. ED. 1 (repealing Article 52(4), but a provision containing the same
wording
was
added
in
Article
53(c)),
available
at
http://archive.epo.org/epo/pubs/oj007/01_07/special_edition_1_epc_2000.pdf.
59
E.I. du Pont de Nemours & Co., 1986 O.J. E.P.O. at 304 (“The fact that a chemical product
has both a cosmetic and therapeutic effect when used to treat the human or animal body does not
render the cosmetic treatment unpatentable.”).
60
Id. at 305.
61
See, e.g., Patents Act, 1977, c. 37 § 4 (U.K.) (“[A]n invention shall be taken to be capable of
industrial application if it can be made or used in any kind of industry, including agriculture.”),
available at http://www.legislation.gov.uk/ukpga/1977/37/pdfs/ukpga_19770037_en.pdf; UNITED
KINGDOM INTELLECTUAL PROP. OFFICE, EXAMINATION GUIDELINES § 4(1) (July 2011), available
at http://www.ipo.gov.uk/practice-sec-004.pdf; Basheer et al., supra note 8, at n.82
(“Illustratively, Section 4A of the 1977 Act in the UK mirrors Article 53(c) of the EPC.”); see also
Press Summary, Supreme Court of the U.K., Human Genome Sciences Inc. (Appellant) v. Eli Lilly
and Company Limited (Respondent) [2011] UKSC 51, (Nov. 2, 2011) available at
http://www.eplawpatentblog.com/2011/November/2011.11.02%20HGS%20v%20Eli%20Lilly%2
0-%20Press%20Summary.pdf (“There is very little UK authority on the topic of industrial
applicability, particularly as regards biological material and the applicable principles are really to
58
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C. Canada
The Canadian requirement of utility differs from that of the rest of the world
by making it effectively impossible to maintain patents in which no actual
working embodiments existed as of the filing date. The reason for this distinction
is the doctrine of sound prediction. Understanding the Canadian requirement
therefore requires an understanding of the role that the doctrine of sound
prediction plays in it.
In Canada, an invention is “any new and useful art, process, machine,
manufacture or composition of matter, or any new and useful improvement in any
art, process, machine, manufacture or composition of matter.”62 In light of this
statutory basis, the Canadian Intellectual Property Office (CIPO) provides in its
Manual of Patent Office Practice (MOPOP) that utility “is an essential aspect of
an invention” and “can be considered as a requirement for an invention to be
operable, controllable and reproducible.”63 Thus, an invention is operable if it
works for its intended purpose.64

be found in the jurisprudence of the EPO and the Board . While the reasoning in each decision of
the Board is not binding upon national courts, the courts should normally follow the jurisprudence
of the EPO, particularly where the Board has adopted a consistent approach to an issue in a
number of decisions as is the case with regard to the application of Article 57 to patents for
biological material.” (citations omitted)). On the issue of industrial applicability, the court in
Human Genome Sciences allowed the appeal, finding that the lower court failed to follow the
principles of the law by:
[L]ooking for a description that showed a particular use for the product [that]
had actually been demonstrated, rather than that the product had plausibly been
shown to be usable for the purposes of research work which the Board must
have taken to have regarded as an industrial activity in itself.
Id. (citations omitted).
62
Canadian Patent Act, R.S.C. 1985, ch. P-4, § 2, available at http://lawslois.justice.gc.ca/PDF/P-4.pdf; CANADIAN INTELLECTUAL PROP. OFFICE, PATENT OFFICE,
MANUAL OF PATENT OFFICE PRACTICE § 12.02 (1998 ed., rev. Dec. 2010) [hereinafter MOPOP],
available at http://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/h_wr00720.html.
63
MOPOP, supra note 62, § 12.08 (which also provides that “[t]he utility of [a particular]
invention must be specific . . . practical . . . and credible.”).
64
Id. § 12.08.01 (“Where the utility of an invention is self-evident to the person skilled in the
art, and no particular promise has been made in regard to any advantages of the invention (e.g. if
the invention was to simplify a known invention), the self-evident utility is sufficient to meet the
required standard. Where, however, the inventors promise that their invention will provide
particular advantages (e.g. will do something better or more efficiently or will be useful for a
previously unrecognized purpose) it is this utility that the invention must in fact have. Although
an invention need only have one use in order to be patentable, where several uses are promised the
applicant must be in a position to establish each of them. For example, if a composition is
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In its interpretation of the statute, the Supreme Court of Canada has held that
utility does not exist if “the invention will not work, either in the sense that it will
not operate at all or, more broadly, that it will not do what the specification
promises that it will do”65 but that “[i]f when used in accordance with the
directions contained in the specification the promised results are obtained, the
invention is useful in the sense in which that term is used in patent law.”66 An
invention also must be controllable and reproducible such that “the desired result
must inevitably follow when the invention is put into practice.”67 Inventions that
are merely “arrived at by chance” and “cannot be reliably reproduced” therefore
lack utility.68
Utility must be established as of the time a patent is applied for and cannot be
supported by evidence occurring after the filing date.69 To show utility, an
applicant can: (1) disclose embodiments of the invention that actually work; or (2)
disclose soundly predicted embodiments.70 The latter factor is referred to as the
doctrine of sound prediction.
The doctrine of sound prediction was invoked by the Canadian Supreme Court
in Apotex Inc. v. Wellcome Foundation Ltd., which held that applicants must
demonstrate that a claimed invention’s promised utility, or “promise of the

promised to be useful as a drug, the applicant must be in a position to show that it is useful in the
therapy of at least one disease. If, however, it is promised to be useful as a drug for treating many
diseases, the applicant must be in a position to establish its utility [see 12.08.03 & 12.08.05] in
treating each of the diseases.”).
65
Consolboard, Inc. v. MacMillan Bloedel (Sask.), Ltd., [1981] 1 S.C.R. 504, 525 (Can.); see
also MOPOP, supra note 62, § 12.08.01.
66
Consolboard, Inc. [1981] 1 S.C.R. 504, at 526; see also Unifloc Regents, Ld. v. Newstead
Colliery, Ld. [1943] 60 R.P.C. 165, 184 (Can.).
67
MOPOP, supra note 62, § 12.08.02. The MOPOP notes “that the idea that the ‘desired result
must inevitably follow’ can refer to an accepted degree of success of a particular repetitive mass
production method,” and the accepted degree of success can vary with particular arts. Id.
68
Id.
69
Apotex, Inc. v. Wellcome Found. Ltd., [2002] 4 S.C.R. 153, para. 46 (Can.) (It is not enough
for an applicant “to be able to buttress speculation with post-patent proof, and thereby to turn
dross into gold.”); see also MOPOP, supra note 62, § 12.08.05. If the application claims priority
to an earlier application, the claims are only valid insofar as the priority document establishes the
utility of invention described in the claims. Id.; cf. In re Brana, 51 F.3d 1560 (Fed. Cir. 1995)
(establishing utility by using a declaration prepared and submitted during the prosecution of the
application showing a person of ordinary skilled in the art would not have doubted the asserted
utility).
70
Apotex, [2002] 4 S.C.R. 153; see also MOPOP, supra note 62, § 12.08.03 (stating that
disclosure of soundly predicted embodiments can be shown in applications “for which an
appropriate basis exists upon which this utility can be predicted.”).
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patent” as it is known in Canada,71 is “soundly predicted” as of the filing or
priority date if no actual working embodiment exists.72 In doing so, the Supreme
Court departed from the “patent friendly” origins of the doctrine of sound
prediction that accepted the promise of the patent unless there was evidence of a
lack of utility.73 The Supreme Court was seeking to prevent applicants from
“buttress[ing] speculation with post-patent proof,” thereby allowing applicants to
be rewarded for patenting what was effectively a guess.74 Although the
Commissioner is required “by law” to reject a patent application where the
invention is merely “arrived at by chance” and “cannot be reliably reproduced,”75
the Court reasoned that the burden should be placed on the applicant to first
establish utility before requiring the attacker to prove invalidity. 76 Following
Apotex, CIPO amended the MOPOP to incorporate the doctrine of sound
prediction into the examination procedure.77
Despite being referred to commonly as a “utility requirement,” the doctrine of
sound prediction is unconcerned with whether the claimed invention can actually
perform the promise of the patent.78 Instead, the doctrine looks solely at whether
the applicant could have reasonably inferred that the claimed invention was
suitable for the promise of the patent based on the evidence available at the filing
or priority date.79 According to Apotex, the doctrine of sound prediction has three
71

Since “promise of the patent” is the accepted Canadian term for promised utility, we will use
it here.
72
MOPOP, supra note 62, § 12.08.05. If the application claims priority to an earlier
application, the claims are only valid insofar as the priority document establishes the utility of
invention described in the claims. Id. It is not enough for an applicant “to be able to buttress
speculation with post-patent proof, and thereby to turn dross into gold.” Id. (quoting Apotex,
[2002] 4 S.C.R. 153, para. 46 (Binnie, J.).
73
See, e.g., Monsanto Co. v. Comm’r of Patents [1979] 2 S.C.R. 1108, 1121–22 (Can.) (“In my
opinion the Commissioner cannot refuse a patent because the inventor has not fully tested and
proved it in all its claimed applications. This is what he has done in this case by refusing to allow
claims 9 and 16 unless restricted to what had been tested and proved before the application was
filed. If the inventors have claimed more than what they have invented and included substances
which are devoid of utility, their claims will be open to attack. But in order to succeed, such attack
will have to be supported by evidence of lack of utility. At present there is no such evidence and
there is no evidence that the prediction of utility for every compound named is not sound and
reasonable.”).
74
Id. at 1127.
75
Apotex, [2002] 4 S.C.R. 153 (citing the Canadian Patent Act, supra note 62, § 40; see also
MOPOP, supra note 62, § 12.08.02).
76
Id.
77
MOPOP, supra note 62, § 12.08.02. The MOPOP notes “that the idea that the ‘desired result
must inevitably follow’ can refer to an accepted degree of success of a particular repetitive mass
production method,” and the accepted degree of success can vary with particular arts. Id.
78
Apotex, [2002] 4 S.C.R. 153.
79
Id.
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prongs, requiring: (i) a factual basis, (ii) a line of sound reasoning based on the
factual basis that leads to the desired result, and (iii) the provision of sufficient
disclosure in the specification.80
The factual basis prong can be established by examples of what could be
found in “scientifically accepted laws or principles, in data forming part of the
state of the art and which is referred to in the description, or in information
forming part of the common general knowledge of the person skilled in the art.”81
The factual basis must be established by evidence linked to a date that predates
the filing date or earliest priority date.82 As such, according to Lilly, if an
applicant neglects to include disclosure within the specification and cannot
otherwise establish a factual basis preceding the filing date, any application in
Canada claiming priority to an earlier priority application may be invalidated even
if that earlier application arose in a jurisdiction that does not require the provision
of a factual basis.83
The general test for the sound reasoning prong of the doctrine of sound
prediction is whether a person of ordinary skill in the art would accept the logic
presented in the line of reasoning and derive from the prediction that the invention
will provide the promise of the patent.84
Although no inventor is required to understand why their invention
works, this does not dilute the requirements for a sound prediction.
If an inventor cannot articulate a line of reasoning to soundly
connect their factual support (e.g. their examples) to the remaining
matter of their claims, they are not entitled to the full breadth of
their claims.85

80

Id.
MOPOP, supra note 62, at § 12.08.04a.
82
G.D. Searle & Co. v. Novopharm Ltd. [2007] F.C. 81, para. 97 (Can.). The United States
and other jurisdictions do not have comparable requirements. See supra note 69.
83
Eli Lilly Can. Inc. v. Apotex Inc., [2009] F.C.A. 97 (Can.).
84
Apotex, [2002] 4 S.C.R. 153; see also MOPOP, supra note 62, § 12.08.04b (“Since a sound
line of reasoning is directed to a person skilled in the art, those elements of the sound line of
reasoning that would be self-evident to the person skilled in the art in view of their common
general knowledge do not need to be explicitly disclosed in the application . . . . It is not possible
to provide exhaustive guidance on the types of reasoning which may be found to be ’sound.’ If
brief, however, the soundness of a line of reasoning can be effectively assessed by asking whether
the person skilled in the art (represented during examination by the examiner) would accept the
logic presented in the line of reasoning and derive from the sound prediction as a whole an
expectation that the invention will provide the promised utility.”).
85
MOPOP, supra note 62, § 12.08.04b; see also Monsanto Co. v. Comm’r of Patents, [1979] 2
S.C.R. 1108 (Can.).
81
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The result is that the court or a patent examiner must subjectively evaluate the
scientific thought process of the applicant.
For example, Canadian Patent No. 2, 225,626 was at issue in the post-Apotex
case of Allergan, Inc. v. Minister of Health, and claimed a new use for a
brimonidine compound as a topically applied neuro-protectant for the optic nerve
and retina of humans from damage from glaucoma or ocular hypertension.86 In
response to an action for infringement, the defendant asserted that the patent
lacked utility since the tests disclosed in the specification upon which the patent
applicant relied to illustrate utility were only in vivo tests in rats rather than
topical testing in humans.87 To evaluate utility under the doctrine of sound
prediction, the court was required to determine whether the results of the rat
testing provided sufficient basis for a sound prediction that the claimed compound
could provide the stated utility in treating humans.88 In other words, the court, as
the legal fact-finder, must judge the scientific reasonableness of the applicant’s
thought process regarding the chosen test procedure.89
According to the Canadian Court of Appeal in Lilly, the disclosure prong of
the Apotex sound doctrine analysis requires that “the patent must provide a
disclosure such that a person skilled in the art, given that disclosure, could have as
the inventors did, soundly predicted that the invention would work once reduced
to practice.”90 The doctrine of sound prediction therefore places an additional

86

Allergan, Inc. v. Minister of Health [2011] F.C. 1316, para. 24 (Can.).
Id. para. 211. Because the tests were not performed on humans, “the utility of that subject
matter could not be soundly predicted as of the priority date . . . .” Id. para. 193.
88
“The doctrine of sound prediction has three components, namely: [that] . . . the inventor
must have had an articulable . . . and sound line of reasoning from which the desired result can be
inferred from the factual basis . . . .” Id. para. 216. “Therefore, the key question that remains is
whether the '626 Patent disclosed the factual basis on which a POSITA could soundly predict in
June 1996 that the topical administration of brimonidine would have a neuroprotective effect in
humans, once the invention was reduced to practice.” Id. para. 220 (citing Merck & Co. v. Apotex
Inc., [2010] F.C. 1265, para. 521 (Can.)).
89
Allergan, Inc. [2011] F.C. 1316, para. 220. The Court ultimately found that the patent did
not lack utility as: (1) the in vivo drug administration would have allowed the drug to navigate to
the eye, (2) the included results demonstrated that the drug produced the proposed effect despite in
vivo administration, and (3) expert testimony that the results would suggest to a POSITA that
drugs would have a similar effect in humans. Id. para. 223.
90
Eli Lilly Can. Inc. v. Apotex Inc., [2009] F.C.A. 97, para. 18 (Can.). “The requirement for
proper disclosure means that the person skilled in the art has to, through the specification [alone] .
. . be provided with sufficient information to understand the basis of the sound prediction and to
practice the entire scope of the claimed invention.” MOPOP, supra note 62, § 17.03.02c (citing
Eli Lilly Can. Inc. v. Apotex Inc. [2008] F.C. 142, para. 164). While elements of the factual basis
and/or the sound line of reasoning that form part of the common general knowledge need not be
disclosed, elements known only to the applicant must be included in the description.
87
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burden on applicants not only to assert utility but also to explain a basis for the
assertion.91
This outcome is a departure from pre-Lilly jurisprudence in Canada.92 In
Consolboard Inc. v. MacMillan Bloedel (SASK), the Supreme Court of Canada
previously had held that the “new and useful” requirement is distinct from the
requirement of what the specification must disclose in a patent application.93
Specifically, the Supreme Court reasoned that the “new and useful” requirement
imposes a condition precedent, from which the disclosure requirement is
independent.94 The Supreme Court held, however, that the inventor was not
obligated, as part of the “new and useful” requirement, to describe in the
specification why the invention is useful so long as the specification describes the
invention in sufficient detail such that it can be practiced.95 The current sound
prediction disclosure requirement as incorporated within the MOPOP following
Lilly, however, obligates applicants to describe a basis of a sound prediction of
utility “through the specification alone.”96
Thus, according to the doctrine of sound prediction, an examiner or court must
first construe the promise of the patent of the claimed invention before evaluating
whether the specification provides a sound line of reasoning linking the construed
promise of the patent to the factual basis thereof. If the utility of the claimed
invention is misconstrued, a proper determination of whether a sound prediction
exists cannot be made. Further, because applicants are not required to explicitly
identify the utility in the specification, the utility of a claimed invention can be
misconstrued by fact finders such that the sound prediction analysis may not be
targeted properly to that which the applicant intended. The result can be
conflicting conclusions as to the promise of the patent.
91

We have considered whether the proper disclosure prong effectively creates a new written
description requirement, or whether it merely shifts the statutory basis with respect to an existing
written description requirement, but found this to be beyond the scope of this article. In the future
we would like to explore whether Apotex effectively creates a new written description requirement
by the third prong of the doctrine of sound prediction, given that the doctrine arises under § 2 of
the Patent Act rather than § 27(3), which governs all other Canadian written description
requirements.
92
The shift in the doctrine of sound prediction began with the Supreme Court decision Apotex,
and was expanded with the Federal Court of Appeal’s decision in Lilly. See supra notes 15–16.
93
Consolboard, Inc. v. MacMillan Bloedel (Sask.), Ltd., [1981] 1 S.C.R. 504 (Can.) see also
Canadian Patent Act § 27(3) (1996).
94
Consolboard, Inc., [1981] 1 S.C.R. 504 at 527 (the court distinguished the new and useful
requirement from the disclosure requirement: “The first is a condition precedent to an invention,
and the second is a disclosure requirement, independent of the first.”).
95
See id.
96
Eli Lilly Can. Inc. v. Apotex Inc., [2009] F.C.A. 97 (Can.); MOPOP, supra note 62, §
12.08.04c.
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Illustrating the risks associated with this approach, in 2011 the Federal Court
of Appeal rendered two decisions pertaining to the same patent and reached
opposite conclusions as to utility. In Pfizer Canada Inc. v. Canada, the Federal
Court of Appeal upheld a finding that Canadian Patent No. 1,339,132 (the ‘132
Patent) was not lacking in utility based on the test results disclosed in the
specification.97 However, in the subsequent case of Apotex Inc. v. Pfizer Canada
Inc., which dealt with the same ‘132 Patent, the Federal Court of Appeal held that
the patent was invalid for lacking utility.98 In the latter case, the Federal Court of
Appeal found that the judge had incorrectly construed the utility of the claimed
invention, and it held that had the judge correctly construed the utility
requirement, the judge would have found that the patent was invalid for lack of
utility.99
Canadian patent law therefore significantly departs from that of the United
States and Europe via the doctrine of sound prediction, which requires applicants
to provide, at the time of filing, the factual basis and line of reasoning for a
prediction of the promise of the patent. It is also a departure from existing
international patent agreements to which Canada is a party.
III.

TREATIES AND OTHER INTERNATIONAL AGREEMENTS

Many of the similarities in the requirements for patentability among the
United States, Europe, and Canada may be attributed to treaty obligations, and to
the general trend toward harmonization that has resulted from our increasingly
interconnected global economy. A fundamental goal of each of the agreements
discussed below, whether the agreement is specifically directed to patents and
intellectual property or is a broader agreement that includes patent and intellectual
property provisions, is harmonization and the creation of international norms to
permit the equal treatment of inventions and inventors across borders. The
doctrine of sound prediction and the heightened utility requirement that it creates
arguably serve to defeat that goal.
A. Paris Convention
The United States, the countries of Europe, and Canada are among the
contracting states of the Paris Convention for the Protection of Industrial Property
(Paris Convention).100 The Paris Convention is administered by the World
97

See Pfizer Can., Inc. v. Canada, [2011] F.C.J. 406, para. 37 (Can.).
Apotex Inc. v. Pfizer Can. Inc., [2011] F.C.A. 236, para. 32 (Can.).
99
Id. para. 52–53.
100
Contracting Parties, WIPO,
http://www.wipo.int/treaties/en/ShowResults.jsp?lang=en&treaty_id=2 (last visited Feb. 17,
2012). The Paris Convention has a total of 174 contracting parties. Id.
98
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Intellectual Property Organization (WIPO), which also administers the Patent
Cooperation Treaty (PCT) and the Patent Law Treaty (PLT), discussed infra, both
of which are Special Agreements under Article 19 of the Paris Convention.101
A bedrock principle of the Paris Convention is national treatment, which
requires each contracting state to grant the same protection to nationals of the
other contracting states as it grants to its own nationals.102 The doctrine of sound
prediction, however, tends to disadvantage foreign nationals and thus arguably
impinges on the principle of national treatment. By insisting that applications
disclose supporting evidence at a level of proof not required by foreign
applicants’ own national jurisdictions (and therefore not of the type that foreign
applicants typically disclose in their priority applications), the doctrine of sound
prediction renders applications filed by foreign nationals and their ensuing patents
especially subject to invalidation for lack of utility.
B. PCT
The Patent Cooperation Treaty (PCT) entered into force in 1978 and was
created to provide applicants with a user-friendly, cost-effective, and efficient
system for filing international patent applications.103 Under the PCT, an applicant
may seek patent protection in some or all of the 144 member countries
simultaneously by filing a single international application.104 Canada, the United
States, and all of the European countries have ratified the PCT and are PCT
contracting states.105
The PCT and the Regulations under the PCT set forth harmonizing
requirements for the international application. Moreover, according to Article 11
of the treaty, an international application has the same legal effect as a national
application in each member country in which an applicant chooses to pursue

101

See WIPO-Administered Treaties, WIPO, http://www.wipo.int/treaties/en/index.jsp (last
visited Feb. 17, 2012). WIPO administers a total of 24 treaties, including those that prescribe
norms of intellectual property protection (for example, the PLT), those that establish global
protection systems (for example, the PCT), and those that create intellectual property classification
systems. Id.
102
Paris Convention for the Protection of Industrial Property art. 2, Mar. 20, 1883, 21 U.S.T.
1583 [hereinafter Paris Convention] (as amended Sept. 28, 1979), available at
http://www.wipo.int/treaties/en/ip/paris/pdf/trtdocs_wo020.pdf.
103
See Patent Cooperation Treaty pmbl., June 19, 1970, 28 U.S.T. 7645 [hereinafter PCT],
available at http://www.wipo.int/pct/en/texts/pdf/pct.pdf.
104
See id. art. 1, 3; WIPO, PCT Applicant’s Guide - International Phase, Annex A
[hereinafter PCT Applicant’s Guide], http://www.wipo.int/pct/guide/en/gdvol1/pdf/gdvol1.pdf.
105
See PCT Applicant’s Guide, supra note 104.
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patent protection.106 The international application, when undergoing national
phase examination in a member country, is then subject to the same national laws
and requirements as a national application filed in that member country.107
Chapter 14 of the PCT International Search and Preliminary Examination
Guidelines (PCT Guidelines) addresses industrial applicability, which is deemed
to be synonymous with utility.108 The PCT Guidelines consider an invention to be
industrially applicable if it has specific, substantial, and credible utility.109 The
methodology for assessing industrial applicability under the PCT Guidelines is to:
(1) determine what the applicant has claimed;110 and (2) determine whether a
person skilled in the art would recognize the claimed invention to have industrial
applicability.111 Identical to the EPO Examination Guidelines, the PCT
Guidelines provide that “[i]n most cases, industrial applicability will be selfevident and no more explicit description on this point will be required.”112
Article 27(1) of the PCT addresses the national requirements that member
countries may impose on international applications: “No national law shall require
compliance with requirements relating to the form or contents of the international
application different from or additional to those which are provided for in this
Treaty and the Regulations.”113 In accordance with Article 27(1), member
countries therefore should not implement form or content requirements that
exceed or differ from those of the PCT, as such requirements work against the
international filing concept and violate the terms of the PCT.114 The PostConference Documents contained in the Records of the Washington Diplomatic
Conference on the PCT, which include a chronological account of the main
106

See
About
the
Patent
Cooperation
Treaty,
WIPO,
http://www.wipo.int/pct/en/treaty/about.html (last visited Feb. 17, 2012); WIPO, PROTECTING
YOUR INVENTIONS ABROAD: FREQUENTLY ASKED QUESTIONS ABOUT THE PATENT COOPERATION
TREATY (PCT) 3–4 (Apr. 2006) [hereinafter PROTECTING YOUR INVENTIONS ABROAD],
http://www.wipo.int/export/sites/www/pct/en/basic_facts/faqs_about_the_pct.pdf (last visited Feb.
17, 2012).
107
See PROTECTING YOUR INVENTIONS ABROAD, supra note 106, at 14–15
108
PCT GUIDELINES, supra note 2, § 14.01.
109
Id. § A14.01[1]. The PCT Guidelines provide alternative guidelines for utility and
industrial applicability, such that “[a]n International Authority may rely upon either.” Id. §
A14.01. Both utility and industrial applicability should be familiar from the discussion supra Part
II. Much of the language and many of the examples given in the Appendix to Chapter 14 are the
same as or very similar to that which appears in the MPEP, EPO Examination Guidelines and
MOPOP; accordingly, the discussion will not be repeated here.
110
PCT GUIDELINES, supra note 2, § 14.04.
111
Id.
112
Id. § 14.05; cf. EPO EXAMINATION GUIDELINES, supra note 3 and accompanying text.
113
PCT, supra note 103, art. 27(1).
114
See id.
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decisions and consultations leading to the adoption of the PCT and its
Regulations,115 state that “[f]orm and contents mean not only the physical
requirements and the identification data but also the form and manner of
describing and claiming.”116
Rule 5.1 of the Regulations under the PCT is directed to the manner of the
description and provides that the description in an international application
should:
[I]ndicate explicitly, when it is not obvious from the description or
nature of the invention, the way in which the invention is capable
of exploitation in industry and the way in which it can be made and
used, or, if it can only be used, the way in which it can be used.117
An international application therefore must demonstrate, either explicitly or
implicitly, the way in which the invention is capable of being exploited and used,
i.e., the invention’s utility. However, the PCT in Rule 5.1 contemplates
variations in the manner in which an invention will be described based upon the
nature of the invention, and it therefore abstains from dictating the particular
manner in which utility must be substantiated.118 The sole exception is expressly
set forth in Rule 5.2 for nucleotide and/or amino acid sequence disclosures, for
which the PCT requires a sequence listing.119 In all other cases, if a member
country requires evidence in a particular form in respect of utility, it may only
oblige the applicant to furnish such evidence during prosecution in the national
phase.
Despite Rule 5, the Canadian Court of Appeal has ruled, as for example in the
Lilly case, that there is an additional requirement that applicants filing Canadian
patent applications through the PCT must face where the invention is based on a
sound prediction.120 In such cases, applicants must not only disclose the factual
basis and line of reasoning for their sound prediction, but they must also provide
the disclosure in the patent specification as filed.121 An additional requirement of
115

WIPO, POST-CONFERENCE DOCUMENTS: RECORDS OF THE WASHINGTON DIPLOMATIC
CONFERENCE,
741,
¶
1
(1970),
available
at
http://www.wipo.int/export/sites/www/pct/en/texts/pdf/washington_p739_to_764.pdf.
116
Id. at 751, ¶ 57.
117
Regulations Under the PCT, R. 5.1(a)(vi) (July 1, 2011), available at
http://www.wipo.int/pct/en/texts/rules/r5.htm. The Rule continues: “[T]he term ‘industry’ is to be
understood in its broadest sense as in the Paris Convention for the Protection of Industrial
Property.” Id.; see supra note 48.
118
Id.
119
Id. at R. 5.2.
120
Eli Lilly Can. Inc. v. Apotex Inc., [2009] F.C.A. 97, para. 14 (Can.).
121
Id.
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this sort concerning the contents of an application is contrary to, and indeed
defeats the purpose of, the PCT.122
C. PLT
The Patent Law Treaty (PLT),123 the scope of which covers both national and
regional applications, is also directed toward procedural standards of patent
protection to be provided by member states.124 The PLT aims “to harmonize and
streamline formal procedures in respect of national and regional patent
applications and patents.”125
The United States and Canada each signed the PLT but have not yet ratified it.
Among the European Patent Organisation member countries, the following are
PLT member states: Albania, Denmark, Estonia, Finland, France, Hungary,
Latvia, Lithuania, Macedonia, Montenegro,126 the Netherlands, Romania, Serbia,
Slovakia, Slovenia, Sweden, Switzerland, and the United Kingdom.127
Article 6(1) of the PLT extends the form and contents requirements of the
PCT to all patent applications, not just international ones, by prohibiting member
countries from demanding compliance with any requirement relating to form and
contents other than those provided for in the PCT.128 Moreover, Article 6(6) of the
122

See supra note 113. Surprisingly, in reaching its decision in the Lilly case, the Court of
Appeal relied upon PCT Article 27(5), which provides in part that “[n]othing in this Treaty and the
Regulations is intended to be construed as prescribing anything that would limit the freedom of
each Contracting State to prescribe such substantive conditions of patentability as it desires.”
Substantive conditions of patentability, however, do not include the contents of the application,
but rather relate to novelty, inventive step, and utility. Moreover, the article expressly provides
that the freedom to prescribe does not extend to conditions of patentability “constituting
requirements as to the form and contents of applications.” PCT, supra note 103, art. 27(5); Lilly,
[2009] F.C.A. 97, para. 19.
123
Treaties, Laws, and Practices: Patent-Related Treaties Administered by WIPO, WIPO,
http://www.wipo.int/patent-law/en/treaties.html (last visited Feb. 16, 2012).
124
Summary
of
the
Patent
Law
Treaty
(2000),
WIPO,
http://www.wipo.int/treaties/en/ip/plt/summary_plt.html (last visited Feb. 16, 2012).
125
Id.
126
Montenegro is an EPO extension state. Extension States, EUROPEAN PAT. OFF.,
http://www.epo.org/about-us/organisation/member-states/extension-states.html (last visited Feb.
16, 2012).
127
Compare Member States of the European Patent Organisation, EUROPEAN PAT. OFF.,
http://www.epo.org/about-us/organisation/member-states.html (last visited Feb. 16, 2012), with
Contracting
Parties:
Patent
Law
Treaty,
WIPO,
http://www.wipo.int/treaties/en/ShowResults.jsp?lang=en&treaty_id=4 (last visited Feb. 16,
2012).
128
Patent Law Treaty art. 6(1), June 1, 2000, U.N.T.S. Reg. No. I-41939 (“[Form or Contents
of Application] Except where otherwise provided for by this Treaty, no Contracting Party shall
require compliance with any requirement relating to the form or contents of an application
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treaty limits a patent office’s authority to require applicants to file evidence “in
the course of the processing of the application only where that Office may
reasonably doubt the veracity of that matter.”129 The regulations under the PLT
require the patent office to state its reason for doubting that veracity.130
D. TRIPS and NAFTA
The Agreement on Trade-Related Aspects of Intellectual Property Rights
(TRIPS) is another treaty to which the United States, European countries, and
Canada are obligated.131 Canada and the United States are also signatories to the
North American Free Trade Agreement (NAFTA),132 which, like TRIPS, provides
that "patents shall be available for any inventions, whether products or processes,
in all fields of technology, provided they are new, involve an inventive step and
are capable of industrial application.”133 TRIPS “establishes minimum levels of
protection that each government has to give to the intellectual property of fellow
[World Trade Organization] members.”134 Non-discrimination is a core goal, not
only as between nationals and foreigners, but also as to the technological field of
an invention, the place of its creation, and whether it was imported or locally
produced.135 TRIPS has another important principle: “[I]ntellectual property
protection should contribute to technical innovation and the transfer of

different from or additional to: (i) the requirements relating to form or contents which are
provided for in respect of international applications under the Patent Cooperation Treaty . . . .”).
129
Id. art. 6(6).
130
Regulations Under the Patent Law Treaty, R. 5, WIPO (Jan. 1, 2006),
http://www.wipo.int/treaties/en/ip/plt/trtdocs_wo039.html.
131
See Members and Observers, Understanding the WTO: The Organization, WORLD TRADE
ORG., http://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm (last visited Feb. 16,
2012).
132
North American Free Trade Agreement, U.S.-Can.-Mex., Dec. 17, 1992, 32 I.L.M. 289
(1993) [hereinafter NAFTA], available at http://www.ustr.gov/trade-agreements/free-tradeagreements/north-american-free-trade-agreement-nafta. Mexico is the third NAFTA signatory.
Id.
133
Agreement on Trade-Related Aspects of Intellectual Property Rights art. 27.1, April 15,
1994,
1869
U.N.T.S.
299
[hereinafter
TRIPs],
available
at
http://www.wto.org/english/res_e/booksp_e/analytic_index_e/trips_02_e.htm#article27; NAFTA
art. 1709.1. “Capable of industrial application” and “useful” are synonymous in the agreements.
Compare TRIPS, supra, with NAFTA, supra note 132.
134
Understanding the WTO: The Agreements, Intellectual Property: Protection and
Enforcement,
WORLD
TRADE
ORG.,
http://www.wto.org/english/thewto_e/whatis_e/tif_e/agrm7_e.htm (last visited Feb. 16, 2012).
135
See
Overview:
The
TRIPS
Agreement,
WORLD
TRADE
ORG.,
http://www.wto.org/english/tratop_e/trips_e/intel2_e.htm (last visited Feb. 16, 2012).
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technology. Both producers and users should benefit, and economic and social
welfare should be enhanced.”136
In an effort to strike a balance between the objective of providing incentives
for pharmaceutical invention and the demands of providing access to public
health, the TRIPS Agreement has paid special attention to the patenting of
pharmaceutical products. For example, the TRIPS Agreement permits member
countries to benefit from important flexibilities, including the adoption of
compulsory licensing provisions to help ensure the adequate supply of
pharmaceuticals, but it stops short of permitting differential treatment in the
examination of pharmaceutical patent applications.137
A country that has ratified the Paris Convention, the PCT and/or the PLT has
agreed to treat all patent applications filed in that country uniformly, regardless of
whether the applications are filed under one of those conventions or the national
laws of the country. Imposing national form and contents requirements beyond
those of the harmonizing international treaties undermines a fundamental purpose
of the agreements: uniform treatment of domestic and foreign-origin applications,
irrespective of the convention under which the foreign-origin application is filed.
A country that has ratified the TRIPS Agreement, moreover, has agreed not to
single out applications in particular areas of technology for discriminatory
treatment. The body of treaties and agreements thus forms part of an international
patent law framework within which patent applicants operate. This framework is
increasingly valued as patent applicants pursue global families of patent
applications and patents.138
IV.

AN INTERJURISDICTIONAL CASE STUDY

Given the frequency with which owners of technology seek protection for
their inventions in multiple countries,139 it is not infrequent for patent or patent
application members of a single patent family to be the object of similar litigation
in several jurisdictions simultaneously. The following case study involves
judicial (courts in Canada and the United States) and administrative (EPO
Technical Board of Appeal in Europe) treatment of a patent family owned by the
136

Understanding the WTO: The Agreements, Intellectual Property: Protection and
Enforcement, supra note 134 (emphasis added). “The [TRIPS] Agreement covers five broad
issues: how basic principles of the trading system and other international intellectual property
agreements should be applied; how to give adequate protection to intellectual property rights[;]
how countries should enforce those rights adequately in their own territories[;] how to settle
disputes on intellectual property between members of the WTO[; and] special transitional
arrangements during the period when the new system is being introduced.” Id.
137
Id.
138
See supra note 9 and accompanying text.
139
See supra note 9 and accompanying text.
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pharmaceutical company AstraZeneca. The patent family originated with a
Swedish patent application140 filed on May 28, 1993 that was generally directed to
optically pure salts of omeprazole,141 which have a superior therapeutic profile to
omeprazole salts having mixed enantiomers.142 On May 27, 1994, the applicant
filed European and PCT applications claiming priority to the Swedish parent
application.143 The applicant subsequently filed Canadian, United States, and
other national phase applications based on the PCT application, with priority
being claimed back to the Swedish application.144
The Canadian patent, No. 2,139,653 (‘653 patent), was challenged in 2010 in
AstraZeneca Canada Inc. v. Apotex Inc., in which Apotex alleged that the ‘653
patent was invalid for lack of utility.145 The patent describes omeprazole as a
gastric acid secretion inhibitor “useful as [an] antiulcer agent[s],” but can have
two possible enantiomers.146 As such, the patent describes and claims the present
invention as a series of omeprazole salts having a single enantiomer
(esomeprazole) and a process for making single enantiomer compounds having
improved pharmacokinetic and metabolic properties.147 Instead of looking to the
stated utility of the claimed compounds, the court reasoned that the utility of the
claimed invention was an “improved therapeutic profile” made possible by the
single enantiomer salts.148
In response to this court-constructed utility,
AstraZeneca presented evidence that prior to the priority date of the Canadian
patent, AstraZenca researchers had found that pure salts of enantiomers, including
esomeprazole, could provide improved therapeutic results. The court nevertheless
rejected the evidence because the report detailing the information was not
140

S.E. Application No. 19931830A (filed May 28, 1993); PCT Application No.
PCT/SE94/00830 (filed May 27, 1994).
141
Omeprazole is a chemical compound that acts as a proton pump inhibitor for treating gastric
disorders. Omeprazole, DRUGBANK, http://www.drugbank.ca/drugs/DB00338#pharmacology (last
updated Feb. 14, 2012).
142
Enantiomers are different configurations of substituents on a tetrahedral carbon or other
atom. GEORGE ODIAN, PRINCIPLES OF POLYMERIZATION 621 (4th ed. 2004).
143
E.P. Application No. 1 020 460A (filed May 27, 1994) (now issued as E.P. Patent No. 1 020
460B); PCT Application No. PCT/SE94/00830 (filed May 27, 1994).
144
C.A. Application No. 2139653A (filed December 08, 1994) (now issued as C.A. Patent No.
2139653B); U.S. Patent Application No. 08/376,512 (filed January 23, 1995) (now issued as U.S.
Patent 5,714,504).
145
AstraZeneca Can. Inc. v. Apotex Inc., [2010] F.C. 714 (Can.).
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C.A. Patent No. 2139653B p. 1, ll. 12–22.
147
Id.
148
AstraZeneca Can. Inc., [2010] F.C. 714, para. 82–84. The court’s reasoning seems to
deviate from that of other countries since the nature of “improved” is not a concern for utility but
rather for obviousness. Under Canadian law, patents are awarded for inventions which are not
devoid of utility, and the measure of an invention’s improvement over the art should be a separate
concern.
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presented until after the filing date of the Canadian application and was not
mentioned in the specification.149 Consequently, the Court invalidated the claims
at issue as lacking a sound prediction, because the applicant failed to show that as
of the priority date the inventors had a factual basis for a prediction that an
esomeprazole salt of a particular purity would have the utility indicated in the
patent.
In contrast, in Astrazeneca AB v. Hanmi USA, Inc., Hanmi alleged that U.S.
Patent 5,714,504 (‘504 patent), an equivalent application to the Canadian ‘653
patent, was invalid for lack of enablement, written description, and other theories,
but it did not even assert that the patent was invalid for lack of utility, although
the Canadian ‘653 patent had already been invalidated on that ground.150
Although the defendant argued that the specification of the ‘504 patent was
lacking in virtually every way, the defendant did not raise lack of utility, no doubt
because the stated utility of the compounds as gastric acid secretion inhibitors,
which was expressly taught in the patent specification, would be considered
sufficient to meet the utility requirement under the U.S. law.151
The European counterpart to the Canadian ‘653 patent and the United States
‘504 patent was European Patent No. 0652872 (‘872 patent). Its fate was
addressed in an EPO opposition proceeding.152 The decision of the EPO
Technical Board of Appeal in that case was to revoke certain claims of the ‘872
patent, and in reaching its decision, the Board relied upon the “use” constructed
by the Canadian Court to invalidate the ‘653 Patent.153 As with the Canadian
court, the Board based its decision to revoke the patent on the “improved
therapeutic profile.” However, unlike the Canadian counterpart case, the Board
did not invalidate the patent for lack of utility, but instead held that the “improved
therapeutic profile” from single enantiomer salts was obvious to a person of skill
in the art.154 As in the United States counterpart case, the Board accepted the
proposed use, and even relied upon the proposed use, without questioning its
validity.

149

Id. para. 86–90.
AstraZeneca AB v. Hanmi USA, Inc., No.11–760(JAP), 2011 WL 5526009, at *6 (D.N.J.
Nov. 14, 2011).
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Though this litigation remains pending, utility remains unchallenged. Id.
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Case No. T 0401/04, Boards of Appeal of the EPO (December 19, 2006), available at
http://www.epo.org/law-practice/case-law-appeals/pdf/t040401eu1.pdf.
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PRACTICAL IMPLICATIONS OF CANADA’S DOCTRINE OF SOUND PREDICTION

The doctrine of sound prediction effectively imposes a heightened utility
requirement on patent applicants in Canada and has broad implications, both
nationally and internationally. First, the heightened utility requirement may
create a new, potentially unintended class of unpatentable subject matter unique to
Canada if selectively used to target a particular type of invention. Second, it
exceeds existing international utility standards, raising questions with respect to
Canada’s obligations under international treaties and potentially leading to
disparate treatment of domestic and foreign-origin applications within Canada.
Finally, it could present a significant hurdle to increased global patent law
harmonization going forward.
With respect to policy, others have noted that utility challenges to Canadian
patent applications have been almost exclusively directed at pharmaceutical
patents.155 Therefore, the doctrine of sound prediction, or at least its focused
application, may be an attempt to implement a policy change in Canada with
respect to certain classes of inventions, namely pharmaceutical. Canada has been
accused in the past of “treating patent holders in the field of pharmaceutical
inventions . . . less favorably than inventions in all other fields of technology,”
which resulted in a complaint being filed against Canada under the WTO TRIPS
Dispute Resolution procedures.156 The patent system, however, should not be
manipulated to implement such a policy change. Rather, policy issues should be
addressed transparently if it is desired, on some level, to promote a new course.
Turning to the international agreements, as a signatory to the Paris
Convention, PLT, PCT, TRIPS, and NAFTA, Canada has agreed to treat all
patent applications filed in its patent office uniformly, regardless of whether the
applications are filed under one of the international conventions (e.g., the Paris
Convention, PLT and PCT) or the national law of Canada. 157 Imposing national
form and content requirements beyond those of the harmonizing international
155

See supra note 12 and accompanying text.
Panel Report, Canada – Patent Protection of Pharmaceutical Products, WT/DS114/R (Mar.
17, 2000). This treatment was alleged to violate Canada’s obligations under Article 27.1 of
TRIPS. Id.; see generally supra Part III.D. Canada was also accused of violating Articles 28.1
and 33 of TRIPS. Id. Ultimately, Canada was found to be in compliance with Articles 27.1 and
28.1 (with respect to § 55.2(1) of the Canadian Patent Act) but in violation of Article 28.1 (with
respect to § 52.2(2) of the Canadian Patent Act). Id. at 174. Article 28.1 of TRIPS addresses
rights conferred on patent owners. TRIPS, supra note 133, art. 28.1. Following the Report of the
Panel, Canada announced it would implement the Panel’s findings, and in October 2000 revoked
the necessary regulations. KRISTEN DOUGLAS & CELIA JUTRAS, CANADIAN PARLIAMENTARY
INFO. AND RESEARCH SERV., PRB 99-46E, PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS
IN CANADA – CHRONOLOGY OF SIGNIFICANT EVENTS, (Rev’d Oct. 6, 2008).
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See supra Part III.
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treaties, which is an effect of Canada’s doctrine of sound prediction, undermines
uniform treatment of domestic and foreign-origin applications, irrespective of the
convention under which the foreign-origin application is filed.
Furthermore, the doctrine of sound prediction creates potential traps that can
ensnare foreign158 applicants. As discussed supra, United States patent law is
similar to that of Canada and requires that an invention must be useful in order to
be patentable.159 Specifically, a specific, substantial, and credible use for the
invention must be disclosed in the specification of a United States patent
application.160 Unlike the Canadian doctrine of sound prediction, under United
States law, the applicant is not required to provide evidence that the connection
between the proposed use and the claimed invention is well-reasoned.161 While
Europe uses the phrase “industrial applicability,” it is analogous to the utility
requirements of United States and Canadian law, as discussed supra.162 An
invention has industrial applicability if the invention “can be made or used in any
kind of industry.”163 Like in United States law, Europe simply requires that the
industrial applicability of the invention be identified and does not require a
showing that the identified industrial applicability be selected as a result of sound
prediction based on the disclosure in the patent.164 As a result, Canadian patent
applications and patents arising from foreign applications or patents, including
United States and European applications or patents, are particularly vulnerable to
invalidation for lacking utility, because United States and European law only
require that the utility be specified, while Canadian law invokes the heightened
evidentiary standard.165 Because other jurisdictions do not require the same
evidentiary standard, foreign-origin specifications likely will not include the
supporting evidence required by Canada alone. Therefore, Canadian patents
based on foreign applications drafted under conventional international utility
requirements, including those of the PCT to which Canada is a signatory party,
are vulnerable to the shifting evidentiary requirements associated with complying
with the doctrine of sound prediction. In imposing on patent applicants
heightened standards that go beyond the letter and intent of the various
international agreements to which Canada is party, Canada has ignored its
international obligations.
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“Foreign” is used here with respect to Canada (i.e., non-Canadian).
U.S. CONST. art. 1, § 8, cl. 8.
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35 U.S.C. §§ 101, 112 (2006); see also MPEP, supra note 5, § 2164.07.
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See supra Part II.
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Finally, Canada’s heightened utility requirements present a barrier to
increased global patent law harmonization. Increased harmonization will be
difficult if nations do not abide by current obligations, never mind anticipated and
future ones intended to harmonize national laws. Given the increasingly global
economy in which innovators operate, jurisdictions that are unwilling or unable to
commit to broadly supported harmonization goals may be left behind, presenting
ever higher hurdles to their innovators and economies.

